Glaxosmithkline Biologicals Sa

Smithkline Beecham Biologicals S.a.

Neovacs

Pierre Vandepapeliere

Moncef Mohamed Slaoui

Géraldine Grouard-vogel

Olivier Dhellin

Bernard Fanget

Camille Roucairol

Geraldine Grouard-Vogel

The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark ofpresented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 &#x3bc;g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 &#x3bc;g of a lipopolysaccharide and between 1 and 30 &#x3bc;g of an immunologically active saponin fraction presented in the form of a liposome.

Vaccine compositions comprising a saponin adjuvant

The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark ofMolina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 &#x3bc;g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 &#x3bc;g of a lipopolysaccharide and between 1 and 30 &#x3bc;g of an immunologically active saponin fraction presented in the form of a liposome.

An immunogenic product including IFN&#x3b1; coupled to a carrier protein molecule is capable to induce in vivo anti-IFN&#x3b1; antibodies and is useful in treating IFN&#x3b1; related conditions.

Method for treating IFNalpha related conditions

A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmitted diseases, for example an HSV glycoprotein D or an immunological fragment thereof, and an adjuvant, especially a TH-1 inducing adjuvant. The use of the vaccine components for the formulation of a vaccine composition for the prevention or treatment of sexually transmitted diseases in female subjects is also described.

Growing community of inventors

Rixensart, Belgium

Pierre Vandepapeliere